Endurant Capital Management’s Aerie Pharmaceuticals AERI Stock Holding History

Endurant Capital Management’s Portfolio AERI Stock Details AERI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-45,366	Closed	-$2.71M	–	86
2017 Q4	$2.71M	Sell	45,366 -11,822	-21%	-$717K	0.83%	45
2017 Q3	$2.78M	Buy	57,188 +4,158	+8%	+$227K	0.84%	42
2017 Q2	$2.79M	Buy	53,030 +19,700	+59%	+$917K	0.79%	37
2017 Q1	$1.51M	Sell	33,330 -29,300	-47%	-$1.31M	0.49%	54
2016 Q4	$2.37M	Buy	62,630 +20,600	+49%	+$779K	0.98%	38
2016 Q3	$1.59M	Buy	42,030 +8,630	+26%	+$190K	0.59%	39
2016 Q2	$588K	Sell	33,400 -9,800	-23%	-$159K	0.2%	71
2016 Q1	$525K	Buy	+43,200	New	+$684K	0.17%	67

Other funds holding AERI

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Endurant Capital Management's AERI Position: Q1 2018 in Review

Endurant Capital Management sold out of Aerie Pharmaceuticals (AERI) in Q1 2018, closing a stake of 45,366 shares — an estimated $2.71M sold.

Endurant Capital Management first reported a position in AERI in Q1 2016 and held it in 8 quarters. The position peaked at $2.79M in Q2 2017. 172 funds tracked by Wall St. Rank hold AERI as of Q1 2018.

Endurant Capital Management reported no remaining Aerie Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
Endurant Capital Management sold 45,366 Aerie Pharmaceuticals shares in Q1 2018, an estimated $2.71M.
Endurant Capital Management first reported a position in Aerie Pharmaceuticals in Q1 2016 and held it in 8 quarters.
Endurant Capital Management's Aerie Pharmaceuticals position peaked at $2.79M in Q2 2017.
172 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q1 2018.

Based on Endurant Capital Management's 13F filing for Q1 2018, filed 15 May 2018.